COMMUNIQUÉS West-GlobeNewswire

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
22/05/2026
BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts [...]
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
22/05/2026
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central [...]
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
22/05/2026
Base shelf prospectus is accessible on SEDAR+ NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp [...]
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
22/05/2026
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech [...]
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
22/05/2026
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
22/05/2026
Strengthening balance sheet on path to Nasdaq uplisting POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, [...]
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
22/05/2026
SAN FRANCISCO, May 22, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer [...]
CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU
22/05/2026
Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained intervention 1,2 CHMP’s [...]
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
22/05/2026
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs , Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or [...]
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
22/05/2026
TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the [...]
SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok
22/05/2026
Japanese-Quality Pico Laser Treatment to Serve the Growing Thai Aesthetic Healthcare Market, with Service Launch Scheduled for June 2026 IRVINE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings [...]
Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options
22/05/2026
For decades, supplement research has not supported cartilage regeneration. A randomized, placebo-controlled study in Pharmaceutical Research documented measurable cartilage regeneration biomarkers at 90 days, a [...]
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
22/05/2026
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- [...]
Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology
22/05/2026
Recent Ebola and Hantavirus Outbreaks Underscore Increasing Institutional Demand for Advanced Disinfection Solutions Across Hospitals, Hotels, Cruise Ships, Transportation Hubs, and Public Facilities FREDERICK, Md., May [...]
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
22/05/2026
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
22/05/2026
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing [...]
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22/05/2026
Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients 1 Expedited approval as an initial [...]
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
22/05/2026
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination [...]
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
22/05/2026
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression CAMBRIDGE, United Kingdom, May 22, 2026 (GLOBE NEWSWIRE) -- STORM [...]

Pages